Introduction
============

Gastric cancer is one of the most aggressive gastrointestinal malignancy and third leading cause of cancer related deaths worldwide [@B1]. Nearly 50% of deaths of gastric cancer were caused by peritoneal metastasis which is frequently present in patients with advanced gastric cancer (AGC), while is very rare in early gastric cancer [@B2], [@B3]. In most cases, gastric cancer with peritoneal metastasis (PMGC) is asymptomatic during a long period and therefore often initially diagnosed intraoperatively which is not benefit for surgeons to determine the most appropriate therapeutic approach [@B4]. Thus, effective method to discriminate PMGC from AGC timely is essential to improve the patients\' quality of life.

Operative diagnostic methods including staging laparoscopy, laparotomy and abdominal cytology are currently used in discrimination of peritoneal metastasis [@B5], [@B6]. However, these methods bring patients high cost, time-consumption and complications from invasiveness such as intra-abdominal organ iatrogenic damages, hemorrhage and infective processes [@B7]. Consequently, non-invasive biomarkers are urgently needed to reduce not only mental and physical trauma but also economic burden of peritoneal metastasis patients. The existing non-invasive diagnostic methods are imaging examinations, such as Computed Tomography (CT), Positron Emission Tomography-Computed Tomography (PET-CT), Magnetic Resonance Imaging (MRI), which have some limitations inaccuracy for preoperatively differentiating PMGC patients from AGC patients[@B2], [@B8], [@B9]. Recent researches had preliminarily demonstrated the predictive effect of serum tumor markers and inflammation associated factors and indexes in differentiating PMGC patients from AGC patients. However, for serum tumor markers including CA125, CA72-4, CA19-9 and CEA, the sensitivity of each individual tumor marker for PMGC prediction was below 50% [@B10], [@B11]. For inflammation associated factors and indexes, although platelet to lymphocyte ratio (PLR) and neutrophil to lymphocyte ratio (NLR) were evaluated in PMGC patients, the area under the receiver operating characteristic curve (AUC) values were only 0.60 and 0.68 respectively for the PMGC diagnosis, respectively [@B2], [@B10], [@B12]. Besides, the number of patients with peritoneal metastasis in most studies of biomarkers is less than 100, which is insufficient to validate the predictive performance [@B11]-[@B16]. Consequently, these markers are deficient for precise diagnosis of peritoneal metastasis because of the absence of accuracy and experimental validation. It is desirable to find new non-invasive predictive factors to differentiate PMGC from AGC in a larger and comprehensive sample set.

Considering the relationship between N-glycans and tumor metastasis, serum N-glycome was analyzed using MALDI-MS in our previous study to discovery the biomarker of PMGC [@B17]. Two of multi-branched N-glycosylation with N-acetylneruaminic acid were significantly decreased in PMGC. Although serum N-glycomics analysis could give a comprehensive overlook of N-glycans, protein-specific glycosylation information is lost. The glycomics analysis of specific glycoprotein would provide more insight into glycosylation actual changes. Immunoglobulin G (IgG), the most abundant glycoprotein in serum, contains a conserved N-glycosylation site at asparagine 297 of its Fc fragment [@B18]. Alternative glycosylation of IgG has significant consequences on cancer immunosurveillance and could be used as predictive markers for gastric cancer. Through LC-ESI-MS, Kristel Kodar et al. profiled the Fc N-glycans of serum IgG samples in 80 patients with gastric cancer and 51 healthy controls. They found the agalactosylated N-glycan was increased in patients with gastric cancer, while galactosylated and monosialylated N-glycans were decreased [@B19]. Besides, IgG N-glycan profile was determined in 35 patients with benign gastric disease and 31 patients with gastric cancer using nano LC-MS. Comparing with benign gastric disease patients, bisected N-glycan and sialylated N-glycans were decreased in gastric cancer patients [@B20]. The analysis of serum IgG N-glycans by FACE was developed in 6 patients with AGC and 6 patients with metastatic gastric cancer, and agalactosylated fucosylated N-glycan was increased in patients with metastatic gastric cancer [@B21]. Nonetheless, the relationship between agalactosylated fucosylated N-glycan and peritoneal metastasis was not evaluated, and the sample size in this study was insufficient to provide a comprehensive analysis of IgG glycome in gastric cancer with metastasis. Until now, no studies have reported IgG N-glycan profiles in PMGC and evaluated their clinical values in distinguishing PMGC from AGC patients.

In the present study, 373 patients with gastric cancer (AGC: n=246, PMGC: n=127) were enrolled to profile specific IgG N-glycans of PMGC patients for the first time. The aim of present study was to (i) identify whether significant differences exist in IgG N-glycans between PMGC patients and AGC patients, and (ii) investigate the predictive values of the alternated IgG N-glycans for patients with PMGC, and (iii) construct an available preoperative prediction glyco-model to differentiate PMGC patients from AGC patients.

Materials and Methods
=====================

Study population and sample collection
--------------------------------------

All serum samples were collected from Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, from March 2015 to February 2018. Exclusion criteria: (1) Patients who ever received chemotherapy or radiation therapy; (2) Patients with distant metastasis; (3) Patients with gastric stump carcinoma. Inclusion criteria: (1) Patients over 18 years old; (2) Patients with histologically proven adenocarcinoma of the stomach or esophagogastric junction (Siewert type 2 or 3); (3) Patients who received CT or PET-CT scan before surgery. Every further postoperative pathological analysis was done for surgery patients, and peritoneal metastasis was confirmed by multidisciplinary team at Zhongshan Hospital.

The cohort composing of 373 serum samples from patients with gastric cancer were randomly assigned into training cohort (161 AGC patients and 88 PMGC patients) and validation cohort (85 AGC patients and 39 PMGC patients) based on a 2:1 ratio. All serum layers were collected and stored at -80°C until analysis. No more than three cycles of freezing/thaw were allowed for any sample. Clinical data of all enrolled patients were retrospectively collected from the database of Zhongshan Hospital and were summarized in Table [1](#T1){ref-type="table"}. The cut-off levels recommended by the manufacturer for CEA, CA19-9, CA125 and CA72-4 were 5.0μg/L, 37U/L, 35U/mL and 10U/mL, respectively. This study was carried out in accordance with the recommendations of the ethical standards of the Medical Ethics Committee, Zhongshan Hospital of Fudan University. The protocol was approved by the Zhongshan Hospital of Fudan University. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

IgG purification from human plasma
----------------------------------

Purification of IgG was described in previous study [@B22]. IgGs from serum samples were isolated using Protein A IgG Purification Kit (Thermo Fisher Scientific). The isolation was manipulated according to the manufacturer\'s instructions. Briefly, 50μL serum was diluted to 100μL using a proprietary Protein A IgG Binding Buffer. Then the mixture was applied to the protein A plate and washed with 500μL of Binding Buffer three times to remove unbound proteins. Last, the bound IgGs were eluted with 200μL of the proprietary IgG Elution Buffer three times in three separate plates. To determine which fractions contained IgG, the absorbance of each fraction was measured at 280nm by a bicinchoninic acid (BCA) test (Thermo Fisher Scientific). And the fractions containing IgG were stored at -20 °C until the N-glycan release.

IgG N-glycans release, enrichment and labeling
----------------------------------------------

As described in previous study, IgG N-glycans were released from IgGs containing elution by incubating with 1μL PNGase F (New England Biolabs) for 12h at 37°C[@B22]. Subsequently, the released N-glycans were purified by porous graphic carbon (PGC) solid-phase extraction. Briefly, a PGC-containing 96-well plate was washed with 200μL of 0.1% trifluoroacetic acid (TFA) (v/v) (Merck) in 80% acetonitrile (ACN) (v/v) (Biosolve) and followed by 0.1% TFA (v/v). The solution of released N-glycans was applied to the PGC containing 96-well plate 3 times to allow complete N-glycans adsorption. Then, 100μL H~2~O was added to remove salts and buffer twice. The N-glycans derived from IgG were eluted with 100μL of 0.05% TFA (v/v) in 25% ACN (v/v). Then the elute was dried in concentrator (Eppendorf) for 3h on 45-degree manual mode followed by labelling with 2-aminobenzamide (2-AB) described by Maja Pucic et al. [@B23]. The labelling mixture was freshly prepared by dissolving 50mg 2-AB (Sigma-Aldrich) and 60mg Sodium cyanoborohydride (Sigma-Aldrich) in 1mL solvent with Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and glacial acetic acid (AcOH) (Merck) mixture (7:3, v/v). A volume of 3μL of labelling mixture was added to each N-glycan sample. Mixing was achieved by shaking for 2min, followed by 2h incubation at 60°C. The labeling reaction was stopped by adding 50μL H~2~O per sample.

Hydrophilic Interaction Chromatography (HILIC)-Ultra Performance Liquid Chromatography (UPLC)
---------------------------------------------------------------------------------------------

The labelled N-glycans were separated by HILIC on a Nexera UHPLC LC-30A (Shimadzu) with fluorescence detector set with excitation and emission wavelengths of 330 and 420nm, respectively. The instrument was under the control of LabSolution software (Shimadzu). Labelled N-glycans were separated on a Waters BEH Amide chromatography column (Waters), 100×2.1mm, 1.7μm BEH particles, with 100mM ammonium formate, pH 4.5, as solvent A and ACN as solvent B. Separation method used linear gradient of 79-56% acetonitrile (v/v) at flow rate of 0.5mL/min in a 26min analytical run. Samples were maintained at 4°C before injection, and the separation temperature of chromatography column was 70°C. Data processing was performed using an automatic processing method with a traditional integration algorithm after which each chromatogram was manually corrected to maintain the same intervals of integration for all the samples. The chromatograms were all separated in the same manner into 24 peaks. In addition to 24 directly measured glycan structures, 15 derived traits were summarized based on the same features from related studies [@B24], [@B25].

Data normalization and statistical analysis
-------------------------------------------

In order to normalize the measurement of IgG glycans, each peak area of glycan was divided by total area of corresponding chromatogram. Multiple t-tests with correction for multiple comparisons, the Sidak-Bonferroni method, was chosen for continuous variables. Specifically, for 15 derived traits analysis, P values smaller than 3.33E-03 (0.05/15) were considered statistically significant and for 24 directly measured glycan peaks, P value should smaller than 2.10E-03 (0.05/24). In order to differentiate patients with PMGC from patients with AGC, multivariate logistic regression model was applied with R package "rms". Only significant differences of 24 directly detect peaks were used as predictors in the model. Receiver operating characteristic (ROC) curves was used to compare the sensitivity and specificity for the predictive performance of glyco-model, and values of area under the curve (AUC) were performed to indicate the accuracy of test. If the AUC value was greater than 0.9 that indicates a "highly accurate" test, while values between 0.8 and 0.9 were considered to be "accurate". When the AUC value was between 0.7 and 0.8, the test was concluded to be "moderately accurate." An "uninformative" test resulted in an AUC value that was between 0.5 and 0.7. All the statistical analyses were performed using R 3.4.3 software and IBM SPSS Statistics version 20.0 software.

Results
=======

Serum IgG N-glycan profiles
---------------------------

IgG N-glycan profiles were analyzed in 246 patients with AGC and 127 patients with PMGC. These patients were randomly assigned into two groups, with nearly two-thirds in the training group (n=249) and a third in the validation group (n=124). The demographic characteristics of the enrolled patients were presented in Table [1](#T1){ref-type="table"}. The age and gender were matched between AGC patients and PMGC patients as far as possible. IgG N-glycomics structures and compositions were determined by UPLC analysis of 2AB-labeled glycans in previous literatures [@B24], [@B25]. The typical glycomics profile was shown in Figure [1](#F1){ref-type="fig"}, which is a representative chromatogram for 24 directly measured glycan peaks. And compositions of 24 directly measured glycan peaks by UPLC were shown in Table [S1](#SM0){ref-type="supplementary-material"}. Besides, fifteen derived traits were calculated based on the same structural features such as fucosylation, galactosylation, sialylation and bisecting type N-glycans (Table [S2](#SM0){ref-type="supplementary-material"}).

Derived traits differences between patients with AGC and PMGC
-------------------------------------------------------------

In order to profile the unique IgG N-glycans of patients with PMGC, fifteen derived traits were compared between patients with AGC (n=161) and patients with PMGC (n=88) in the training cohort. Significant differences were observed in several derived traits (Table [2](#T2){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). Neutral N-glycans (GPN, P=3.83E-09, Figure [2](#F2){ref-type="fig"}A) were decreased in PMGC group. Relatively, total sialylation (GPS, P=4.69E-06, Figure [2](#F2){ref-type="fig"}B) showed an opposite level in PMGC group compared with AGC group. Monosialylation (S1, P=1.78E-06, Figure [2](#F2){ref-type="fig"}C) and disialylation (S2, P=3.48E-13, Figure [2](#F2){ref-type="fig"}D) which contribute to the amounts of total sialylation both showed increased level in PMGC group. Besides, monogalactosylation (G1, P=3.12E-04, Figure [2](#F2){ref-type="fig"}E) decreased in PMGC group. In this cohort, we also found bisecting N-glycan (B, P=1.65E-06, Figure [2](#F2){ref-type="fig"}H) and bisecting N-glycan of neutral IgG glycans (BN, P=1.08E-06, Figure [2](#F2){ref-type="fig"}I) decreased, while fucosylation of neutral glycans (FN, P=2.06E-04, Figure [2](#F2){ref-type="fig"}F) and fucosylation of sialylated glycans (FS, P=6.89E-04, Figure [2](#F2){ref-type="fig"}G) increased in PMGC group compared with AGC group. Furthermore, we evaluate the potential diagnostic performance of these traits using ROC curves (Table [2](#T2){ref-type="table"}). Notably, the AUC values of GPN, GPS and S2 were 0.72 (95%CI: 0.65 to 0.78), 0.71(95%CI: 0.65 to 0.78) and 0.76 (95%CI: 0.69 to 0.82) respectively, which showed moderately accurate differential performance of patients with PMGC.

Predictive model establishment based on the training cohort
-----------------------------------------------------------

Although GPN, GPS and S2 derived from directly measured glycan peaks had a moderately accurate differential performance of patients with PMGC, a predictive glyco-model constructed by directly measured glycan peaks might have a better predictive performance. As displayed in Table [3](#T3){ref-type="table"}, six directly detected glycan peaks were significantly increased in patients with PMGC than in patients with AGC in the training cohort. By contrast, five glycan peaks showed a decreased level in patients with PMGC.

Considering that these glycan peaks showed strong association with PMGC, we attempted to build a predictive glyco-model using multivariate logistic regression in the training cohort (Table [3](#T3){ref-type="table"}). Logistic regression coefficients were utilized to estimate the odds ratios for each of the independent variables. Score estimation of glyco-model, composed by GP6 (H3N5F1), GP9 (H4N4F1(3)), GP11 (H4N5F1(3)), GP21 (H5N4S2) and GP23 (H5N4F1S2), was established on the mathematic formula:

Score=4.49 \* GP6 + 5.42 \* GP9 - 50 \* GP11 + 30.19 \* GP21+ 26.53\* GP23+88.33

Based on the ROC analysis (AUC=0.80, 95%CI: 0.74 to 0.86) in training cohort, we set up the optimal cut-off value of predictive score as 168.60. Patients with predictive score greater than 168.60 will be classified as PMGC cases, values equal to or less than 168.60 will be classified as AGC cases. Under the cut-off value, the discrimination model was able to distinguish the PMGC patients from AGC ones with a sensitivity of 75.00% and specificity of 73.29% (Figures [3](#F3){ref-type="fig"}A and B, Table [S3](#SM0){ref-type="supplementary-material"}).

Validation of the predictive model
----------------------------------

To validate the accuracy of the predictive model, serum IgG N-glycomics analysis was performed in the aforementioned validation sample set composed of 124 serum specimens (AGC: n=85, PMGC: n=39). This model demonstrated an AUC value of 0.77 (95%CI: 0.68 to 0.86) with a sensitivity of 66.67% and a specificity of 76.47%, suggesting a moderately accurate diagnosis (Figures [3](#F3){ref-type="fig"}C and D, Table [S3](#SM0){ref-type="supplementary-material"}). Furthermore, we combined the training cohort and the validation cohort as a combined cohort (AGC: n=246, PMGC: n=127) to further validate the performance of the predictable glyco-model. In this cohort, the AUC value was 0.79 (95%CI: 0.74 to 0.84) with a sensitivity of 72.44% and a specificity of 74.39%, making this glyco-model predictable for differentiation of patients with PMGC (Figure [S1](#SM0){ref-type="supplementary-material"}, Table [S3](#SM0){ref-type="supplementary-material"}). The diagnostic performance of the glyco-model was much better than those serum tumor markers including CEA, CA19-9, CA125 and CA72-4 (Table [S4](#SM0){ref-type="supplementary-material"}).

Finally, to illustrate the predictive workflow of the discriminated glyco-model, we selected two preoperative serum samples with or without peritoneal metastasis. Serum IgG N-glycomics analysis of samples and application of the model was conducted (Figures [4](#F4){ref-type="fig"}A and B). The predictive score of these two samples were calculated as 151.44 and 181.79, respectively (Figure [4](#F4){ref-type="fig"}C). Under the cut-off value of predictive score of 168.60, we predicted that sample A was from AGC cases and that sample B was from PMGC case. These predictions from the model were in line with laparoscopic results (Figure [4](#F4){ref-type="fig"}D).

Discussion
==========

This study represents the first comprehensive analysis of IgG N-glycans in gastric cancer with peritoneal metastasis. By analyzing 127 patients with PMGC and 246 matching controls with advanced gastric cancer, we firstly find that peritoneal metastasis is associated with alterations in the IgG N-glycome composition: (i) increase in IgG sialylation, fucosylation of both neutral and sialylated IgG glycosylation, (ii) decrease in neutral IgG glycosylation, IgG monogalactosylation and bisecting IgG glycosylation. These data may be important to help understand the role of IgG glycosylation in immunosurveillance and mechanism of PMGC.

Peritoneal metastasis, mainly induced by the dissemination of free tumor cells from the primary gastric cancer, is usually associated with a poor prognosis in patients with AGC [@B26]. Median survival of patients without metastasis was 14 months, but only 4 months for patients with peritoneal metastasis [@B27]. As we know, treatment option, decision-making and prognosis of gastric cancer are strongly dependent on the extent of tumor [@B28]. Compared to curable gastrectomy for AGC, an untreatable condition existed in PMGC [@B29]. From this point of view, PMGC needs to be precisely differentiated from AGC before surgery for surgeons to determine the most appropriate therapeutic approach, and avoid unnecessary extensive surgery.

Unfortunately, in clinical practice, it is often difficult to make diagnosis of peritoneal metastasis preoperatively by conventional imaging modalities due to the low sensitivity and cost. A systematic review of imaging in PMGC indicated that although the specificity of imaging methods was more than 0.90, the poor sensitivity for US, EUS, CT and 18F-FDG PET in detecting peritoneal metastasis were 0.09 (95% CI: 0.03 to 0.21), 0.34 (95% CI: 0.10 to 0.69), 0.33 (95% CI: 0.16 to 0.56) and 0.28 (95% CI: 0.17 to 0.44) respectively [@B8]. Therefore, a sensitive examination was urgently needed to be developed to improve the diagnosis of peritoneal metastasis preoperatively.

Due to the non-invasiveness and convenience, serum biomarkers were investigated to predict peritoneal metastasis. Many papers have been published on the relationship between peritoneal metastasis and different tumor markers such as CEA, CA19-9, CA125 and CA72-4. A retrospective study containing 88 patients with PMGC evaluated the diagnostic performance of serum biomarkers. It showed that the sensitivity of CEA, CA19-9 and CA125 were 31.8%, 37.5% and 38.6%, respectively [@B30]. In another study, CEA and CA125 showed a better predictive performance of peritoneal metastasis with a sensitivity of 46.9% and 46.1% [@B10]. Of the combinations of the two markers, CA125 and CA72-4 together showed a higher sensitivity of 68% [@B10]. When combined all four tumor markers and lysyl oxidase (LOX), the diagnostic sensitivity increased to 91.3% [@B11]. In the present study, we also evaluate the performance of these tumor biomarkers. Compared with AGC group, all these four markers were increased in PMGC group. The AUC values of CEA, CA19-9, CA125 and CA72-4 were 0.54, 0.63, 0.63 and 0.62, respectively (Table [S4](#SM0){ref-type="supplementary-material"}). Consistent with the literatures, our results showed these serum tumor markers cannot predict PMGC effectively. Recently, some serum markers reflecting the systemic inflammatory response and immune responses of gastric cancer were indicated to be associated with peritoneal metastasis. Platelet to lymphocyte ratio (PLR) was an independent indicator to predict peritoneal metastasis, the AUC value was 0.60 with a sensitivity of 69.3% and a specificity of 51% [@B2]. The neutrophil to lymphocyte ratio (NLR) was also evaluated in PMGC group, and the AUC value was 0.68 with a sensitivity of 63.8% and a specificity of 67.4% [@B12]. Besides, serum C-reactive protein (CRP) and serum albumin (Alb) were significantly related to the presence of peritoneal metastasis [@B12]. Therefore, the relationship between tumor and the body inflammatory status has received increasing attention. However, none of these serum markers showed satisfied accuracy to predict PMGC.

As one of the key factors in humoral immunity, IgG is involved in antibody-dependent cell-mediated cytotoxicity (ADCC), opsonization, and complement-dependent cytotoxicity (CDC) [@B31]. The structure and biological activity of IgG is influenced by its Fc-glycosylation. Decreased IgG galactosylation and sialylation lead to pro-inflammatory antibody response. Furthermore, elevated occurrence of bisecting GlcNAc and lack of core fucose results in an increased ADCC activity [@B25]. Altered IgG glycosylation profiles have been described in many kinds of cancers including gastric cancer [@B31]-[@B33]. The galactosylated and sialylated IgG N-glycans were decreased and core fucosylated N-glycan was increased in gastric cancer [@B19], [@B20]. However, there is no study identify whether significant difference in IgG N-glycans existed between patients with PMGC and patients with AGC. In addition, we previously conducted serum N-glycomics analysis in gastric cancer including 46 PMGC patients and 46 AGC patients to find potential biomarkers, and found H6N5F2L2E1 and H7N6F1L2E1 decreased in PMGC group(H: hexose, N: N-acetylhexosamine; F: fucose, L: α-2,3 N-acetylneruaminic acid; E: α-2,6 N-acetylneruaminic acid) [@B17]. Since the relative abundance of these two glycans is low and N-glycomics analysis requires more professional operations, we want to find a more effective predictive biomarker for PMGC.

Based on the aforementioned information, we focused on the significance of IgG N-glycans in differential diagnosis of peritoneal metastasis by using UPLC analysis. We analyzed IgG N-glycan profiles in 373 patients including 127 PMGC patients. Since the incidence of peritoneal metastasis accounted for 14% in gastric cancer, it is difficult to collect PMGC patients [@B27]. This is the first time IgG N-glycans profiled in such a large group with peritoneal metastasis. Based on the large sample size, significant changes in peritoneal metastasis were founded to build and further validate the predictive model. Through comparing 15 derived traits in training cohort, we found that neutral N-glycans (GPN) were decreased in PMGC group. Relatively, sialylated N-glycans (GPS) including monosialylation (S1) and disialylation (S2) were increased in PMGC group. And monogalactosylation showed a decreased level in PMGC group. Interestingly, the results showed an opposite trend to the previous study [@B19], [@B20]. Therefore, we compared these derived traits between healthy controls (n= 94) with both AGC group (n=246) and PMGC group (n=127), and we found the trend of galactosylation and sialylation in gastric cancer was consistent with the previous literature (data not shown). These results showed that IgG glycosylation changes were dynamic in gastric cancer and could reflect immune response in patients with PMGC. Increased sialylation indicated anti-inflammatory antibody response in peritoneal metastasis. We also found there was an increased level in fucosylation of both neutral N-glycans (FN) and sialylated N-glycans (FS) in PMGC group. Differently, total bisecting GlcNAc (B) and bisecting GlcNAc of neutral N-glycans (BN) showed a decrease level in patients with PMGC. These results suggested that ADCC activity might be decreased in peritoneal metastasis.

Several derived traits have potential to be differential biomarkers of peritoneal metastasis. The AUC values of GPN, GPS and S2 were more than 0.70, which means moderately accurate diagnostic performance. In order to find a more accurate diagnostic model, we analyzed 24 directly measured glycan peaks in the training cohort. In order construction the predicted logistic regression model, five differentially expressed IgG glycans were selected including GP6, GP9, GP11, GP21, GP23, each were weighted with a corresponding coefficient. The final score =4.49 \* GP6 + 5.42 \* GP9 - 50 \* GP11 + 30.19 \* GP21+ 26.53\* GP23+88.33. The glyco-model showed a more accurate differential performance for peritoneal metastasis with a sensitivity of 75.00% and a specificity of 73.29%. And the performance of this glyco-model were validated in both the validation cohort (n=124, AUC=0.77) and the combined cohort (n=373, AUC=0.79). To our knowledge, this is the first study to identify specific IgG N-glycan features of PMGC, providing potential glyco-model to distinguish the PMGC from AGC. Accurate diagnosis of peritoneal metastasis before the operation is beneficial for PMGC patients to avoid the mental and physical trauma from unnecessary surgery.

In conclusion, we profiled IgG N-glycans in advanced gastric cancer patients with or without peritoneal metastasis and identified several derived traits either up-regulated or down-regulated in patients with peritoneal metastasis for the first time. Based on the largest sample of PMGC as we know, we established and validated a glyco-model to predict peritoneal metastasis. Further studies are still needed to validate the differential potential of this glyco-model in a larger study and identify the role of protein glycosylation in pathology of peritoneal metastasis.
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![**Representative Ultra Performance Liquid Chromatography (UPLC) chromatogram of serum IgG N-glycan profiles.** A total of 24 chromatographic peaks was shown.](jcav10p2811g001){#F1}

![**The abundance of the nine representative derived traits in patients with PMGC and patients with AGC in the training cohort.** The N-glycans were grouped according to their structural features: neutral N-glycans (GPN) (A); total sialylation (GPS) (B); monosialylation (S1) (C); disialylation (S2) (D); monogalactosylation (G1) (E); fucosylation of neutral glycans (FN) (F); fucosylation of sialylated glycans (FS) (G); bisecting N-glycan (B) (H); bisecting N-glycan of neutral glycans (BN) (I).](jcav10p2811g002){#F2}

![**Efficacy prediction of discriminate glyco-model of the training cohort and the validation cohort.** A and C, Plots of ROC results for distinguishing PMGC samples from the AGC samples. Glyco-model shows good diagnostic efficacy in predicting PMGC in training cohort (AUC=0.80, 95%CI: 0.74 to 0.86) (A) and validation cohort (AUC=0.77, 95%CI: 0.68 to 0.86) (C). B and D, the logistic regression predictive score for each patient of the training (B) and validation set (D). Logistic regression predictive score was calculated with the formula, Score=4.49 \* GP6 + 5.42 \* GP9-50 \* GP11 + 30.19 \* GP21+ 26.53\* GP23+88.33.](jcav10p2811g003){#F3}

![**Analysis workflow of prediction.** Typical base peak of the serum specimen in positive ion mode(A). Identification and quantification of the five IgG glycan of GP6, GP9, GP11, GP21 and GP23 (B). Logistic regression predictive score and outcome prediction of the two samples(C). Typical images of abdominal cavity by staging laparoscopy (D). The circled parts are typical peritoneal metastasis.](jcav10p2811g004){#F4}

###### 

Clinicopathological characteristics of all patients

                                                Training cohort N=249   Validation cohort N=124                        
  --------------------------- ----------------- ----------------------- ------------------------- -------------------- -------------------
  **N**                       161               88                      85                        39                   
  **Age (min-max)**           59.71 (33-83)     60.51 (27-87)           59.84 (31-83)             57.87 (38-81)        
  **Gender (male/female)**    119/42            55/33                   67/18                     24/15                
  **Tumor location**          Upper 1/3         25                      8                         10                   5
  Middle 1/3                  45                30                      28                        13                   
  Lower 1/3                   70                33                      36                        10                   
  Mixed                       16                13                      10                        9                    
  Data Absent                 5                 4                       1                         2                    
  **Differentiation**         High + Moderate   28                      28                        16                   8
  Poor                        125               43                      67                        23                   
  Data Absent                 8                 17                      2                         8                    
  **Lauren classification**   Intestinal        37                      8                         22                   2
  Diffuse                     44                15                      18                        4                    
  Mixed                       50                6                       29                        9                    
  Data Absent                 30                59                      16                        24                   
  **CEA**                     Mean (Min-Max)    8.48 (0.4-94.9)         9.11 (0.5-209.5)          14.94 (0.4-1.9)      16.40 (0.5-372.8)
  \<5ng/mL                    88                42                      55                        18                   
  ≥5ng/mL                     38                21                      14                        12                   
  Data Absent                 35                25                      16                        9                    
  **CA19-9**                  Mean (Min-Max)    140.95 (1-8982)         237.01 (1-5682)           23.38 (1.5-170.9)    428.02 (4.8-4210)
  \<37U/mL                    94                38                      49                        12                   
  ≥37U/mL                     23                25                      11                        16                   
  Data Absent                 44                25                      25                        11                   
  **CA125**                   Mean (Min-Max)    20.95 (5.5-225.3)       52.89 (4-281.2)           31.76 (5.6-401.3)    46.94 (9-246)
  \<35U/mL                    86                34                      46                        14                   
  ≥35U/mL                     13                22                      7                         8                    
  Data Absent                 62                32                      32                        17                   
  **CA72-4**                  Mean (Min-Max)    16.73 (0.6-300)         43.58 (0.8-300)           18.97 (0.35-257.3)   30.23 (1-300)
  \<10U/mL                    70                24                      39                        14                   
  ≥10U/mL                     19                28                      15                        6                    
  Data Absent                 72                36                      31                        19                   

^a^AGC: Advanced gastric cancer; ^b^PMGC: Peritoneal metastasis gastric cancer.

###### 

Serum IgG N-glycans derived traits in advanced gastric cancer with or without peritoneal metastasis

  Glycan traits   Significant   Tendency in PMGC   P value    Mean of AGC   Mean of PMGC   AUC    95% CI
  --------------- ------------- ------------------ ---------- ------------- -------------- ------ --------------
  GPN             \*            ↓                  3.83E-09   90.87         87.51          0.72   0.65 to 0.78
  GPS             \*            ↑                  4.69E-06   9.04          12.41          0.71   0.65 to 0.78
  S1              \*            ↑                  1.78E-06   7.30          9.47           0.67   0.60 to 0.74
  S2              \*            ↑                  3.48E-13   1.74          2.94           0.76   0.69 to 0.82
  G0                                               0.13       37.86         36.12          /      /
  G1              \*            ↓                  3.12E-04   37.70         36.47          0.64   0.57 to 0.71
  G2                                               0.73       14.93         14.73          /      /
  F                                                0.52       93.60         93.75          /      /
  FN              \*            ↑                  2.06E-04   95.95         96.86          0.66   0.59 to 0.73
  FS              \*            ↑                  6.89E-04   84.07         87.38          0.58   0.51 to 0.65
  B               \*            ↓                  1.65E-06   22.23         18.61          0.69   0.62 to 0.75
  BN              \*            ↓                  1.08E-06   22.61         18.75          0.69   0.62 to 0.76
  BS                                               0.38       16.75         17.25          /      /
  FG1                                              0.04       28.29         29.09          /      /
  Gal-ratio                                        0.60       0.56          0.55           /      /

###### 

List of the 11 serum IgG N-glycans that were evaluated to be significantly different between PMGC and AGC

  Glycan peak   Significant   Tendency in PMGC   P value    Mean of PMGC   Mean of AGC
  ------------- ------------- ------------------ ---------- -------------- -------------
  GP6           \*            ↑                  2.53E-05   7.60           9.52
  GP7           \*            ↑                  2.67E-04   0.39           0.51
  GP9           \*            ↓                  1.73E-03   9.70           8.95
  GP10          \*            ↑                  5.84E-08   6.20           7.85
  GP11          \*            ↑                  3.97E-08   0.79           1.04
  GP15          \*            ↑                  6.90E-05   1.60           1.96
  GP16          \*            ↓                  1.82E-08   2.17           1.64
  GP18          \*            ↓                  1.92E-05   5.77           4.33
  GP21          \*            ↓                  7.29E-05   0.75           0.57
  GP23          \*            ↓                  2.09E-13   0.95           0.44
  GP24          \*            ↑                  1.46E-09   1.21           0.71
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